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Introduction
Endometriosis is a chronic disease that affects women
of reproductive age. Malignant transformation in en-
dometriosis  is considered to be an unusual event, only
occurring in 0.7–0.1% of cases. However, according to
several epidemiological studies, endometriosis is related
to increased risk of various tumors with the best evidence
for ovarian cancer. Endometriosis has been found to be
associated with clear cell and endometrioid histological
sub-type of ovarian carcinoma [1]. Some studies indicate
that patients with endometriotic lesions harbor a higher
risk for developing endometrial cancer. However the as-
sociation between endometriosis and endometrial cancer
is not well defined [2]. The etiopathogenesis  of en-
dometriosis and endometrial cancer is multifactorial, but
a yet unidentified common link may exist. Although new
scientific findings are still necessary to fully explain the
exact mechanisms between these two disorders, it seems
that endometriosis and endometrial cancer share common
etiological mechanisms, including estrogen stimulation
and chronic inflammation [1]. Also in literature rare cases
of uterine sarcoma, about 3% of all uterine malignancies,
associated with endometriosis have been reported [3].
There are a few literature studies regarding the relation-
ship between enometrial stromal tumours (ESTs) and en-
dometriosis.
Case Report  
The authors report a case of a 47-years-old Italian woman,
G2P2, referred to the present Gynecology Emergency Department
with severe pelvic pain since three days. On her medical history,
she had two vaginal deliveries, no previous surgery, and no fa-
miliarity for gynecologic malignancies. Transvaginal ultrasonog-
raphy revealed: uterus increased in side, nonhomogen-
eous endometrial echo pattern, hyperechoic and vascularized tis-
sue in the uterine cavity, measuring 25×12 mm in diameter, a 15
×12-mm mass in left ovary, and free fluid in Douglas cavity. Total
body computed tomography revealed a 15-cm partially solid and
partially cystic lesion of left ovarian origin, enlarged lomboaortic
lymph nodes, and ascites. Serum levels of  BhCG, CEA, CA 15.3,
and alpha-fetoprotein were negative, while  CA 125 was 132,20
UI/ml (normal laboratory values 0.00-35.00) and CA 19.9 was
352.24 UI/ml (normal laboratory values 0.00-37.00). The patient
underwent laparotomic surgery in which uterus, ovaries, fallopian
tubes, mass originating from the left ovary, omentum, appendix,
and pelvic and lomboaortic lymph nodes were removed. Cyto-
logical analysis of fluid washed from the abdominal cavity and
peritoneum was performed. The removed material was sent to  cy-
tological and histological laboratory. Histologically,  in the en-
dometrium there was a  localized endometrioid endometrial
carcinoma with evidence of tumor infiltration in the myometrium;
the complex ovarian mass was heterogeneous, characterized by
both solid and cystic areas. The cystic component presented solid
foci and histologically was confirmed as an endometriotic lesion
with endometrioid ovarian carcinoma. The solid component was
composed of pleomorphic round and oval to spindled cells. Their
nuclei were polymorphous vesicular with coarse chromatin and
large nucleoli. The cytoplasm was scant. More than 12 mitotic
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Summary
Endometriosis is a chronic disease that affects women of reproductive age. Malignant transformation in endometriosis is considered
to be an unusual event, only occurring in 0.7–0.1% of cases. However  the association between endometriosis and endometrial cancer
is not well defined. Also in literature, rare cases of uterine sarcoma, about 3% of all uterine malignancies, associated with endometrio-
sis have been reported. The authors report a case of a 47-years-old Italian woman with histologic diagnosis of endometrioid ovarian car-
cinoma arising from endometriosis, endometrioid endometrial carcinoma, and undifferentiated endometrial sarcoma. Therefore there have
been few studies addressing the relationship between endometrial stromal sarcomas (ESS), and endometriosis. Novel scientific findings
are necessary to investigate a possible common pathway and an effective treatment, although complete tumor resection can reduce the
recurrence rate. 
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figures per 10 high power fields were readily identified. Im-
munohistochemical test showed an undifferentiated sarcoma char-
acterized by cells: CK-, vimentin+, p53+, CD34+, WT1+, CD10+,
cKit-, PgR-, ER-, PLAP-, inhibin- alpha, CD99-, CD45, CD30-,
alpha-fetoprotein-, MART1-, S-100-, CD56-, and AML-.  Based
on these findings, the tumor was interpreted as high-grade undif-
ferentiated endometrial sarcoma. Three of the 12 lomboaortic
lymph nodes, two of the nine left-sided obturator lymph nodes,
left parametrium,  and ascites fluid were infiltrated by undifer-
rentiated sarcoma cells. Omentum, appendix, uterine cervix, bi-
lateral paracolpium, right parametrium, and right annex were free
of tumor. In conclusion the results of histologic examination
demonstrated endometrioid ovarian carcinoma arising from en-
dometriosis, endometrioid endometrial carcinoma, and undiffer-
entiated stromal sarcoma. The patient was sent to the present
oncological center where she began chemotherapy with carbo-
platin, taxol, and bevacizumab.
Discussion
Endometriosis is a chronic gynecological benign and es-
trogen-dependent disease that involves approximately 10%
of women of reproductive age. It is characterized by the
presence of endometrial tissue outside the uterus, includ-
ing the ovaries and other pelvic structures. Malignant trans-
formation is a rare complication of endometriosis and it is
considered to be an unusual event (0.7–0.1% of cases) [1].
The relationship between endometriosis and ovarian cancer,
particularly  endometrioid or clear cell carcinoma has been
well established; in contrast, the relationship between en-
dometriosis and endometrial cancer has yet to be deter-
mined [2]. Although endometriosis is not yet established as
a risk factor for endometrial cancer, recent studies have dis-
cussed an influence of the epithelial-to-mesenchymal tran-
sition and stem cells in endometrial cancer. Adult stem cells
occur in endometrial tissue and scientific evidence have
shown a possible role in the pathogenesis of endometriosis
and endometrial cancer [2, 4-7]. Two etiopathogenetic the-
ories were formulated: estrogen stimulation and chronic in-
flammation. In the first theory, endometriosis is an
estrogen-dependent disease that adapts to estrogen-induced
signaling by increased local production [1]. Some studies
have suggested  that there is pathological overexpression
of estrogen receptor A (ERA) in endometriotic stromal
cells, because of reduced methylation of the ERA promoter,
which also suppresses estrogen > (ER >) expression. In en-
dometrial cancer ERA-to-ER > ration has been shown to
be high, with ER > messenger RNA significantly lower in
poorly differentiated endometrial cancer [8-11]. Another
important role may be played by chronic inflammation, be-
cause endometriosis tissue is associated with increased
level of cytokines, chemokines, and prostaglandins [7]. Cy-
clooxygenase 2 (COX-2), an enzyme in biosynthesis of
prostaglandin E2, is elevated in both endometriosis and en-
dometrial cancer. Prostaglandin E2, at first, promotes initial
carcinogenesis and further tumor progression stimulating
cell proliferation and neoangiogenesis, while reducing in
situ immune status. Both theories can be regarded as com-
plementary [8]. A study by Fowler et al. found that the aro-
matase is expressed in 65% of endometrial cancer patients,
as it has not been expressed in normal endometrium [12].
Collins et al. showed an elevated ratio of COX-2 in women
with ER-positive endometrial cancer. The relationship be-
tween, ER and COX-2  could have a synergetic effect [11].
Furthermore Zaino et al. found that in about 30% of pa-
tients with endometriosis had a synchronous endometrioid
type endometrial and ovarian cancers [13]. Endometrial
stromal sarcomas (ESS) in endometriotic lesions is very
rarely reported, and it seems that it may result from sub-
mesothelial pluripotential Müllerian cells [14, 15]. Ex-
trauterine EST can develop in pelvic cavity,
retroperitoneum, fallopian tube, and ovary. The incidence
of EST is approximately 0.2% of all malignant uterine tu-
mors [14, 15]. The 2014 WHO classification  divides ESTs
into endometrial stromal nodule (ESN), low-grade en-
dometrial stromal sarcoma (LGESS), high-grade endome-
trial stromal sarcoma (HGESS), and undifferentiated
uterine sarcoma (UUS) [16]. ESS are divided in low and
high grade tumours according to mitotic activity (< 10 mi-
toses per 10 high power fields for LGESS; 10 or more mi-
toses per 10 high power fields for HGESS) [17]. However,
at present there are controversies surrounding the separa-
tion of ESS based on mitotic count [18]. Regarding UUS
these include a group of high-grade, aggressive tumours
that occur  in older patients. They can present abnormal
postmenopausal uterine bleeding with uterine enlargement
in 70% of cases, pelvic pain, dysmenorrhea, and extrauter-
ine spread in about 30–50% [15]. UUSs present a destruc-
tive infiltrative growth into the uterine wall, associated with
necrosis and/or haemorrhage, lymphovascular invasion,
and increased mitotic activity with atypical figures [16].
The treatment includes total abdominal hysterectomy, bi-
lateral salpingo-oophorectomy, while lymphadenectomy is
controversial [15-17]. The five-year overall survival rate is
about 25–55%. Adjuvant therapy with doxorubicin and/or
ifosfamide is discussed [19]. ESS arising from en-
dometriosis is considered a rare tumor with uncertain eti-
ology. This unusual neoplasm presents a good prognosis,
but 25 years after first diagnosis, metastases and late re-
currence can occur  [20]. The targeted treatment is total ab-
dominal hysterectomy with bilateral salpingo-oopho-
rectomy, because complete tumor resection may reduce the
recurrence rate [7, 19] However in extrauterine ESS, as
well as in disseminated disease, there is a controversial dis-
cussion for the treatment. Some authors recommended a
primary surgical procedure with complete tumor resection
and possible organ resection in absence of the residual dis-
ease. The best choice of adjuvant therapy remains unknown
currently because the response is limited; the radiotherapy
does not change overall survival. Similarly, there have been
no standard recommendations for hormonal therapy [15,
16]. Thus, new therapeutic strategies for this tumor are
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needed. Future investigations should be directed about
PDGFR that was expressed in several cases with ESS aris-
ing from endometriosis for a future possible targeted ther-
apy with  imatinib mesylate. Also in the study by Moinfar
et al. an elevated rate (70%) of ESS tumors demonstrated
positive for EGFR. In 76% of cases of  extrauterine ESSs,
the ovary is the primary site and these can be site of usual
type and pure stromal endometriosis (foci of gland-free en-
dometrial stroma in the ovary) or directly from ovarian stro-
mal cells with neometaplasia into endometrial stromal-type
cells [6, 14]. Ovarian ESSs are rare cancer; in literature
there are about 50 cases. Histological examination is rep-
resented by cells resembling stromal cells of normal pro-
liferative endometrium. These tumors occurred at any age,
but most of them in the fifth and sixth decades [14, 15].
Clinical finding include non-specific abdominal symptoms
attributable to the presence of a pelvic mass; for this reason
often most of ovarian ESSs are diagnosed at an advanced
stage. The patients’ ages range from 20 to 76 years. Ac-
cording to several authors, the traditional division of ESSs
into low and high grade is no longer used. At present, the
differentiation between lesions is not made on mitotic
count, but on the basis of nuclear pleomorphism and necro-
sis [15]. The term “undifferentiated endometrial sarcoma”
(UES) was introduced. UESs are highly aggressive tumours
with a very poor prognosis (less than two years’ survival)
[21]. UES is characterized by severe nuclear pleomor-
phism, high mitotic activity, tumour cell necrosis, and
represents a high-grade sarcoma that lacks specific dif-
ferentiation and that bears no histological resemblance to
endometrial stroma. Therefore the term ESS is now con-
sidered best restricted to LGESS and HGESS and should be
regarded as an undifferentiated sarcoma [4, 15]. Immuno-
histochemical features comprise reactivity to antibodies
specific for vimentin, ER, and CD10, and non-reactivity to
antibodies against CD117, smooth muscle actin (SMA),
and cytokeratin (CK) [5, 6]. CD10 is the acute lym-
phoblastic lymphoma antigen (CALLA) and it is consid-
ered a marker for normal and neoplastic endometrial
stromal cells. This cell surface enzyme reduces cellular re-
sponse to peptide hormones. Thus, several hormone-sensi-
tive and peptide-sensitive cells, as well as their
corresponding tumors, express CD10 antigen as normal en-
dometrial stroma and ESS [6]. Although CD10 has been
defined as marker for ESS, in literature other uterine neo-
plasms like malignant Müllerian mixed tumors, uterine
smooth muscle tumors, adenosarcomas, endocervical ade-
nocarcinomas, uterine tumors resembling ovarian sex cord
tumors, and gestational trophoblastic disease may present
CD10 [6]. CD10 expression of UES of the ovary is not well
defined, and these tumors should be diagnosed after ex-
cluding an undifferentiated carcinoma or a malignant mixed
Müllerian tumor. Recently CD10 immunoreactivity is a
very useful  marker of ESS, but CD10 expression is not of
diagnostic value and  is not indicative of endometrioid stro-
mal differentiation [6, 15]. Regarding progesterone recep-
tor, while ESSs present elevated sensitivity to antibodies
against this antigen, this marker is less specific for differ-
entiating ESS from other mesenchymal neoplasms. Also,
estrogen receptor and CD34 may be more useful in the di-
agnosis of extrauterine extraovarian EST [14, 15].
Conclusion
Larger studies are needed in order to better assess the re-
lationship between endometriosis and endometrial cancer,
to identify a possible molecular link, and to understand
their etiopathogenesis. Therefore there have been few stud-
ies addressing the relationship between EST, ESSs, and en-
dometriosis. Novel scientific findings are necessary to
investigate a possible common pathway and an effective
treatment, although complete tumor resection can reduce
the recurrence rate.  
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